Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 18/20 | 0.74 |
| ▸ | CDK4 | P11802 | 12/20 | 0.74 |
| ▸ | PLK1 | P53350 | 2/20 | 0.74 |
| ▸ | AURKA | O14965 | 6/20 | 0.72 |
| ▸ | CDK9 | P50750 | 5/20 | 0.72 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.72 |
| ▸ | CDK1 | P06493 | 4/20 | 0.72 |
| ▸ | CDK7 | P50613 | 4/20 | 0.72 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.67 |
| ▸ | JAK2 | O60674 | 1/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2074206 | 0.87 | CDK2 (0.69) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL6157713 | 0.86 | CDK2 (0.74) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL4170843 | 0.85 | CDK2 (0.77) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL2289103 | 0.85 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL12589637 | 0.85 | CDK2 (0.82) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL2074508 | 0.84 | CDK2 (0.76) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL27684377 | 0.84 | CDK2 (0.64) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL6157855 | 0.84 | CDK2 (0.71) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL6363136 | 0.83 | CDK2 (0.76) | CDK2CDK4PLK1AURKACDK9 | |
| SCHEMBL6157084 | 0.83 | CDK2 (1.00) | CDK2CDK4PLK1AURKACDK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | claimed |
| CN-1711258-A | Pyrimidine compounds | CYCLACEL LTD (GB) | 2005-12-21 | — | — | CN | claimed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-7897605-B2 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2011-03-01 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-20080287439-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2008-11-20 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| US-7432260-B2 | Pyrimidine compounds | CYCLACEL LIMTED (GB) | 2008-10-07 | — | — | US | disclosed |
| CN-100415740-C | Pyrimidine compounds | CYCLACEL LTD (GB) | 2008-09-03 | — | — | CN | disclosed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| EP-1864983-A1 | PYRIMIDINE COMPOUNDS AS CYCLIN-DEPENDENT KINASE INHIBITORS | Cyclacel Limited (GB) | 2007-12-12 | — | — | EP | disclosed |
| CN-1711258-A | Pyrimidine compounds | CYCLACEL LTD (GB) | 2005-12-21 | — | — | CN | disclosed |
| US-20050192300-A1 | Pyrimidine compounds | CYCLACEL LIMITED (GB) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287439-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | CDK2 1/4885CDK4 7/4885PLK1 85/4885 |
| US-20050192300-A1 | Pyrimidine compounds | CDK2, CCNI, CDK6 | CDK2 1/4885CDK4 7/4885PLK1 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.